Search

Author/Creator Kanzler, S.

1. 2049 AIO-KRK-0109: A randomized phase II trial of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as 1st-line treatment in RAS-wild-type metastatic colorectal cancer (mCRC). (September 2015)

Authors:
Martens, U.M.; Wessendorf, S.; Knorrenschild, J. Riera; Buechner-Steudel, P.; Florschuetz, A.; Atzpodien, J.; Greeve, J.; Kanzler, S.; Ettrich, T.; Lindig, U.; Egger, M.; Hebart, H.; Geissler, M.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S344
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'. (May 2018)

Authors:
Haas, M.; Siveke, J.T.; Schenk, M.; Lerch, M.M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Kanzler, S.; Kunzmann, V.; Ettrich, T.J.; Kruger, S.; Westphalen, C.B.; Held, S.; Heinemann, V.; Boeck, S.
Journal:
European journal of cancer
Issue:
Volume 94(2018)
Page Start:
95
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search